Market Overview

Glaukos Shares Soar After Competing Stent Removed From Market

Glaukos Shares Soar After Competing Stent Removed From Market
Related GKOS
The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie
The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Glaukos Corp (NYSE: GKOS) stock skyrocketed Wednesday after one of the company’s major competitors removed its product from the market.

What Happened

Alcon announced that it's voluntarily withdrawing its CyPass Micro-Stent from the market following new data from a five-year, long-term COMPASS-XT safety study. Alcon also advised opthalmic surgeons to stop implanting the CyPass stents.

Why It’s Important

The CyPass stent was a direct competitor to the Glaukos iStent, and CyPass’ $40 to $50 million in annual revenue is now seemingly up for grabs.

“Accordingly, GKOS should return to positive annual sales growth in the U.S. in CY19 as a significant competitive headwind has been absolved,” Stephens analyst Chris Cooley said Wednesday.

Cooley reiterated an Overweight rating for Glaukos and raised the price target for the stock from $50 to $57.

William Blair analyst Brian Weinstein estimates the news could add up to $50 million to Glaukos’ $186 million in 2019 revenue.

“Overall, this should be viewed as a positive for Glaukos, as a major part of the short thesis was on competition in the core iStent market, mainly from Alcon given its size and presence in the ophthalmic world,” Weinstein said.

William Blair reiterated its Outperform rating on Glaukos.

What’s Next

Investors will be watching for any commentary from Alcon on if and when it could potentially reintroduce CyPass. They will also be watching Glaukos earnings in the next several quarters to see just how much of the CyPass business it can capture — and whether safety concerns have put a damper on the overall market.

Related Links:

The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent

Affimed Shares Soar On $5B Collaboration With Roche's Genentech

Photo courtesy of Glaukos.

Latest Ratings for GKOS

Sep 2018BMO CapitalMaintainsMarket PerformMarket Perform
Aug 2018BMO CapitalMaintainsMarket PerformMarket Perform
Aug 2018JP MorganUpgradesNeutralOverweight

View More Analyst Ratings for GKOS
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Health Care Price Target Reiteration Top Stories Analyst Ratings Best of Benzinga


Related Articles (GKOS)

View Comments and Join the Discussion!

Latest Ratings

CNPRBC CapitalUpgrades34.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Eventbrite IPO Tracks With Growth In Music Festivals

Trade Wars: $200 Billion Is Serious, 3 Scenarios And Currency Reactions For The Upcoming Escalation